Objective: As neonatal blood contains a high proportion of fetal hemoglobin (HbF), it is difficult to use high-performance liquid chromatography (HPLC) method, latex-immunoturbidimetry (LA) method and enzymatic methods, which determine hemoglobin A 1C (HbA 1C ) in order to provide the glycemic control indicators of neonates. In this study, we evaluated glycated hemoglobin (GHb) and glycated albumin (GA) as appropriate indicators of the glycemic control in the neonatal period.
Introduction
It is known that glycation among various proteins is increased in diabetic patients compared with non-diabetic subjects. Some of these glycated proteins are suggested to be involved in the development and progression of chronic diabetic complications. 1 Among these glycated proteins, glycated hemoglobin (GHb) is commonly used as the gold standard to monitor glycemic control in patients with diabetes mellitus. 2, 3 Although high-performance liquid chromatography (HPLC) is most frequently used for the determination of GHb, there are other methods available such as latex-immunoturbidimetry (LA) method, enzymatic method and affinity method. Since lifespan of erythrocytes is approximately 120 days, GHb reflects the plasma glucose for the past few months. Furthermore, GHb measurements are affected by variant hemoglobin and some diseases that shorten the lifespan of erythrocytes, such as hemolytic anemia and renal anemia. Thus, GHb does not properly represent the status of glycemic control in such conditions. 4, 5 Neonatal diabetes mellitus (NDM) is a generic term for diabetes that develops before early infancy, and one in every 300 000 to 500 000 neonates suffers from this disease. 6, 7 Although the pathological condition of NDM is insulin-dependent diabetes mellitus, the etiology of NDM is different from that of type 1 diabetes mellitus. NDM is defined as that it develops within the first 6 months of life, while type 1 diabetes mellitus develops in the period after 7 months of life. Recently, the genes involved in the development of various pancreatic b-cells and their functions have been identified as the causes of NDM. 8, 9 As GHb levels cannot be used as an indicator of glycemic control status in patients with NDM, most of these patients receive insulin therapy to monitor plasma glucose levels alone.
Neonatal blood contains a high proportion of fetal hemoglobin (HbF). Immediately after birth, HbF accounts for 80 to 90%, while hemoglobin A (HbA) accounts for only 10 to 20%. During postnatal periods, HbF is gradually replaced by HbA, and HbA accounts for most of Hb by 6 months after birth. Therefore, because HPLC method, LA method and enzymatic methods determine hemoglobin A 1C (HbA 1C ) specifically, these methods cannot provide neonatal glycemic control indicators. In addition, serum 1,5-anhydroglucitol levels are known to appear to be low in the neonatal period. 10 Fructosamine measurements, which measure absolute amount of glycated proteins, are also low, because serum protein levels are low in neonates. 11, 12 On the other hand, as serum glycated albumin (GA) levels are expressed as ratios relative to serum albumin levels, serum GA levels are not affected by serum protein levels. 12 Accordingly, we hypothesized that serum GA would be an appropriate indicator of glycemic control status in the neonatal period. In this study, we determined GHb levels using various methods and serum GA levels of umbilical cord in order to evaluate the validity of our hypothesis.
Methods

Participants
The subjects were five pregnant women who did not suffer from any complications. The umbilical cord blood samples collected during delivery were used in this study. The institutional committee approved the protocol of this study, and all participants gave their written informed consent.
Analysis
Plasma glucose, serum albumin and hemoglobin were determined by standard laboratory assays. GHb levels were determined by the following five methods: HPLC method using ADAMS-A 1C HA-8160 (Arkray, Kyoto, Japan) 13 and that using HLC-723 G8 (Tosoh, Tokyo, Japan), 14 LA method (RAPIDIA Auto HbA 1C -L; Fujirebio, Tokyo, Japan), 15 enzymatic method (Nordia-N HbA 1C ; Sekisui Medical, Tokyo, Japan) 16 and affinity method (GHb V, affinity mode; Tosoh). 17, 18 All these methods were corrected by using Japan Diabetes Society lot 2 GHb 19 and the normal control range of GHb for adults is from 4.3 to 5.3%. Serum GA was determined by enzymatic method using albumin-specific protease, ketoamine oxidase and albumin assay reagent (Lucica GA-L; Asahi Kasei Pharma, Tokyo, Japan). 20, 21 GA was hydrolyzed to amino acids by an albumin-specific proteinase, and then oxidized by ketoamine oxidase to produce hydrogen peroxide, which was measured quantitatively. Serum GA levels were calculated as the percentage of GA relative to total albumin, which was measured in the same serum sample using a new bromocresol purple method. 22 Normal control of serum GA levels for adults is from 11.0 to 16.0%. Results are expressed as mean ± s.d.
Results
The results of measurements of glycated proteins in umbilical cord blood are shown in Table 1 . By the HPLC method using HA-8160, the peak of HbA 1C that was eluted a little behind HbF was undetected (Figure 1a) . By the HPLC analysis using HLC-723 G8, the prominent peak of HbF was followed by the small peak of HbA 1C , and the level was determined as 1.5 ± 0.2% (Figure 1b) . By the LA method, GHb levels were below the measurement sensitivity. The result of measurement using the enzymatic method was as low as 0.8±0.3%. By the affinity method using borate, a clear peak of GHb was observed and the level was 3.6 ± 0.2%, which was slightly lower than the lower limit of normal controls for adults. Serum GA level was 9.4±1.1%, which was slightly lower than the lower limit of normal controls for adults. Although serum albumin level was slightly low (3.7±0.2 g per 100 ml), both plasma glucose HbA 1C and GA in umbilical cord M Koga et al (94 ± 27 mg per 100 ml) and Hb levels (16.4 ± 1.3 g per 100 ml) were within the normal ranges.
Discussion
By two HPLC methods, LA method and enzymatic method, GHb levels were considerably low compared with normal control ranges for adults. As these techniques determine glycated b-chains specifically, glycated g-chains derived from HbF cannot be determined as GHb. In measurements using the former HPLC instrument, the peak of HbF overlapped with that of HbA 1C because of poor separation by HPLC, and GHb levels were measured high in patients who persistently had HbF. 22 As a result of subsequent improvement of separation by HPLC, the models released after HA-8160 (Arkray) and GHb V (Tosoh) have been able to separate HbF from HbA 1C . As HbA 1C level is calculated by dividing the measured HbA 1C by the whole Hb, the level appears to be low in blood samples containing a large amount of components other than HbA. 23 Neonatal blood contains a large amount of HbF, whereas HbA accounts for only 10 to 20%. For this reason, HbA 1C levels are determined extremely low and such data cannot be used in the clinical setting. HbA 1C levels determined by HLC-723 G8 are considered to contain a part of the peak of HbF (Figure 1b) .
GHb levels determined by the affinity method, which reflect the entire amount of GHb, can be used as an indicator of glycemic control state in the neonatal period. 18, 24 Although the affinity method was used as the main method for measurement of GHb levels, the results of its measurement in umbilical cord blood were reported. According to these reports, the levels of GHb in umbilical cord blood samples collected from diabetic mothers were higher than those from mothers without diabetes mellitus. 25, 27 Later, however, the problem of binding specificity between boronic acid and glycated proteins was pointed out, and so the affinity method has now become rarely used. Furthermore, the speed to form GHbs may be different between HbF and HbA, because g-chain in HbF does not have an N-terminal valine, but has glycation sites at several different amino-residues. Therefore, it is difficult to assume that the GHb levels determined by affinity method may be used as glycemic control marker for NDM.
Similar to the results by the affinity method of GHb, the levels of serum GA in umbilical cord blood were slightly lower than the normal control ranges for adults. Although serum albumin levels in umbilical cord serum were previously shown low, 28 unlike serum fructosamine levels, serum GA levels are not affected by serum protein (albumin) levels. 12 Thus, the previously reported results also showed that GA in umbilical cord serum and GHb levels determined by the affinity method were lower than those of maternal blood samples. As plasma glucose levels in umbilical cord blood were lower than those in maternal blood samples, the lower GA and GHb levels probably reflect the lower plasma glucose levels. [25] [26] [27] In the previous reports, the affinity method was used to determine GA levels in umbilical cord serum. 27 This study is the first report of the results of GA measurement using the enzymatic method.
Serum GA levels, but not GHb levels determined by the affinity method, may be used as glycemic control markers of NDM. The enzymatic method can determine serum GA levels by autoanalyzer, and thus can give the results within short time. In the future, we need to accumulate data on serum GA levels of the patients with NDM to verify whether serum GA levels can be used as an indicator of glycemic control in these patients.
